[ET Net News Agency, 6 December 2021] Shanghai Junshi Biosciences Co., Ltd. (01877)
said the United States Food and Drug Administration (FDA) has expanded the emergency use
authorization (EUA) for etesevimab (JS016/LY-CoV016) and bamlanivimab (LY-CoV555)
administered together (therapy) to include certain high-risk pediatric patients from birth
to under 12 years old for the treatment of mild to moderate COVID-19 as well as
post-exposure prophylaxis.
The therapy has been the first and only authorized neutralizing antibody therapy for
emergency use in COVID-19 individuals under the age of 12, and offers treatment and
prevention options to high-risk individuals of any age. (RC)